Nanoparticles-based delivery system and its potentials in treating central nervous system disorders.

Nanotechnology

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, People's Republic of China.

Published: August 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Central nervous system (CNS) disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD), have become severe health concern worldwide. The treatment of the CNS diseases is of great challenges due largely to the presence of the blood-brain barrier (BBB). On the one hand, BBB protects brain from the harmful exogenous molecules via inhibiting their entry into the brain. On the other hand, it also hampers the transport of therapeutic drugs into the brain, resulting in the difficulties in treating the CNS diseases. In the past decades, nanoparticles-based drug delivery systems have shown great potentials in overcoming the BBB owing to their unique physicochemical properties, such as small size and specific morphology. In addition, functionalization of nanomaterials confers these nanocarriers controlled drug release features and targeting capacities. These properties make nanocarriers the potent delivery systems for treating the CNS disorders. Herein, we summarize the recent progress in nanoparticles-based systems for the CNS delivery, including the conventional and innovative systems. The prerequisites, drawbacks and challenges of nanocarriers (such as protein corona formation) in the CNS delivery are also discussed.

Download full-text PDF

Source
http://dx.doi.org/10.1088/1361-6528/ac85f3DOI Listing

Publication Analysis

Top Keywords

central nervous
8
nervous system
8
cns disorders
8
cns diseases
8
treating cns
8
delivery systems
8
cns delivery
8
cns
6
nanoparticles-based delivery
4
delivery system
4

Similar Publications

Background: The expression and clinical correlation of BRAFV600E mutation and programmed cell death-1 ligand 1 (PD-L1) in children with Langerhans cell histiocytosis (LCH) have been reported, but the conclusions of previous studies are inconsistent. In addition, it has been reported that elevated cathepsin S (CTSS) expression is associated with various cancers. However, there is currently no research on the correlation between CTSS and LCH.

View Article and Find Full Text PDF

Sleep deprivation (SD) is a major contributor to cognitive impairment, often accompanied by central neuroinflammation and gut microbiota dysbiosis. The tryptophan (TRP) pathway, activated via indoleamine 2,3-dioxygenase (IDO), serves as a critical link between immune activation and neuronal damage. Umbelliferone (UMB), a naturally occurring coumarin compound, possesses anti-inflammatory, antioxidant, and microbiota-modulating properties.

View Article and Find Full Text PDF

Ocular relapse in pediatric acute lymphoblastic leukemia (ALL) is rare and typically associated with central nervous system or bone marrow involvement. Anterior segment infiltration as the sole manifestation of relapse is exceptionally uncommon and may mimic noninfectious uveitis, leading to diagnostic delay. We report the case of a 4-year-old boy with a history of B-cell precursor ALL, diagnosed at age 2 and treated according to the ALL IC BFM 2009 protocol.

View Article and Find Full Text PDF

The flavonoid rutin protects against imidacloprid-induced osmotic and electric disruptions in Africanized honey bees.

PLoS One

September 2025

Departamento de Biología, Escuela de Ciencias e Ingeniería, Universidad del Rosario, Bogotá, Colombia.

Honey bees (Apis mellifera) are essential pollinators threatened by sublethal effects of pesticides such as imidacloprid, a widely used neonicotinoid that disrupts the central nervous system. However, many of the systemic effects are poorly understood, especially on the physiological homeostasis of the honey bee. We evaluated the effects of oral administration of imidacloprid and the flavonol rutin on the properties of extracellular fluid (ECF) in Apis mellifera.

View Article and Find Full Text PDF

Spinal muscular atrophy (SMA) is a neuromuscular disease caused by low levels of SMN protein. Several therapeutic approaches boosting SMN are approved for human patients, delivering remarkable improvements in lifespan and symptoms. However, emerging phenotypes, including neurodevelopmental comorbidities, are being reported in some treated SMA patients, indicative of alterations in brain development.

View Article and Find Full Text PDF